UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Pain, fatigue, and loss of appetite are common symptoms of advanced prostate cancer and its treatment. Here’s what you can do to feel better. Talking to your doctor about any advanced prostate c ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer: Sydney, Australia Monday, January 27, 2025, 14:00 Hrs [I ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

This clinically important prostate cancer imaging modality is currently recommended ... PSMA-positive status in the study was determined by 68 Ga-PSMA-11 PET/CT scans. Results from the trial’s key ...